{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:29:30Z","timestamp":1786336170003,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dalbavancin is a long-acting lipoglycopeptide antibiotic with activity against Gram-positive bacteria and is approved for the treatment of acute bacterial skin and skin structure infections. Its pharmacokinetic profile and tolerability make it an attractive option for pediatric infections requiring prolonged therapy, including off-label indications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review of the literature was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to evaluate the safety and effectiveness of dalbavancin in pediatric patients. Studies published between 2010 and 2025 were identified through searches of PubMed, Scopus and Web of Science. Clinical trials, pharmacokinetic studies, systematic reviews and case series were included. In addition, a retrospective observational study of pediatric patients treated with dalbavancin at a tertiary hospital between 2023 and 2025 was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ten studies met inclusion criteria, including clinical trials, pharmacokinetic analyses and pediatric case series. Seven patients (age range 5\u201317 years) were included in the institutional case series, most with significant comorbidities. Infections treated included osteoarticular infections, endocarditis or septic thrombophlebitis, and catheter- or device-related infections. Dalbavancin was primarily prescribed to shorten intravenous therapy, improve adherence and facilitate early discharge. All patients achieved clinical cure without relapse during follow-up, and no adverse events attributable to dalbavancin were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dalbavancin was well tolerated and was associated with favorable outcomes in selected pediatric patients with severe Gram-positive infections, supporting its potential role in facilitating early discharge and outpatient management. Prospective multicenter studies are needed to better define its safety and effectiveness beyond acute bacterial skin and skin structure infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005362","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:00:21Z","timestamp":1786334421000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Expanding the Role of Dalbavancin in Children: A Case Series and Systematic Review"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0649-6544","authenticated-orcid":false,"given":"Victoria","family":"Dom\u00ednguez-Le\u00f3n","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-0676","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Mu\u00f1oz-Vilches","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Rheumatology and Immunology Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-2943","authenticated-orcid":false,"given":"Concepci\u00f3n","family":"\u00c1lvarez Del Vayo Benito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Universitario Virgen del Roc\u00edo, Seville, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter Alfredo","family":"Goycochea-Valdivia","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Rheumatology and Immunology Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Neth","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Rheumatology and Immunology Unit"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14740338.2021.1935864","article-title":"Systematic review and meta-analysis on the safety of dalbavancin.","volume":"20","author":"Monteagudo-Mart\u00ednez","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"R6-20260810","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age.","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0000000000003798","article-title":"Safety and efficacy of dalbavancin and active comparator in pediatric patients with acute bacterial skin and skin structure infections.","volume":"42","author":"Giorgobiani","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3390\/antibiotics13040327","article-title":"Dalbavancin for acute bacterial skin and skin structure infections in pediatrics: insights from continuation therapy experience.","volume":"13","author":"Scarano","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"R10-20260810","first-page":"231","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients: a case series.","volume":"32","author":"Garbo","year":"2024","journal-title":"Infez Med"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/jac\/dkae212","article-title":"Off-label use of dalbavancin in children: a case series.","volume":"79","author":"Gamell","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R13-20260810","first-page":"78","article-title":"Real-world use of dalbavancin for treatment of soft tissue and bone infection in children.","volume":"11","author":"Caselli","year":"2024","journal-title":"Children (Basel)"},{"key":"R14-20260810","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1097\/INF.0000000000004883","article-title":"Case series: off-label use of dalbavancin in pediatric gram-positive infections.","volume":"44","author":"Guill\u00e9n-Mart\u00ednez","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"R15-20260810","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0000000000000646","article-title":"Pharmacokinetics, safety and tolerability of single-dose dalbavancin in children 12\u201317 years of age.","volume":"34","author":"Bradley","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20260810","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/INF.0000000000003764","article-title":"Population pharmacokinetic and PK\/PD target attainment analyses for dalbavancin in pediatric patients.","volume":"42","author":"Carrothers","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/08971900241285521","article-title":"One and done? An evaluation of the clinical outcomes of single- and multi-dose dalbavancin use in the pediatric population.","volume":"38","author":"Morrisette","year":"2025","journal-title":"J Pharm Pract"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s15010-024-02393-9","article-title":"A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.","volume":"53","author":"Leanza","year":"2025","journal-title":"Infection"},{"key":"R19-20260810","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae070","article-title":"Dalba got back? Use of dalbavancin for the treatment of vertebral osteomyelitis.","volume":"11","author":"Streifel","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R20-20260810","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of staphylococcus aureus bacteremia: the DOTS randomized clinical trial.","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"key":"R21-20260810","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna.","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R25-20260810","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin efficacy and impact on hospital length-of-stay and treatment costs in different gram-positive bacterial infections.","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin Drug Investig"},{"key":"R26-20260810","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anpedi.2021.06.013","article-title":"Tasa de cultivos positivos a Staphylococcus aureus resistente a meticilina en servicios de urgencias pedi\u00e1tricos espa\u00f1oles.","volume":"97","author":"Garriga Ferrer-Bergua","year":"2022","journal-title":"An Pediatr (Barc)"},{"key":"R27-20260810","doi-asserted-by":"crossref","first-page":"170","DOI":"10.37201\/req\/113.2023","article-title":"Prevalence and risk factors for methicillin-resistant Staphylococcus aureus infection in children.","volume":"37","author":"Mar\u00edn Oliv\u00e1n","year":"2024","journal-title":"Rev Esp Quimioter"},{"key":"R28-20260810","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1473-3099(16)30024-X","article-title":"Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines.","volume":"16","author":"McMullan","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R29-20260810","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac706","article-title":"Can the future of ID escape the inertial dogma of its past? The exemplars of shorter is better and oral is the new IV.","volume":"10","author":"Davar","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R30-20260810","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/INF.0000000000004343","article-title":"Challenging dogma in the treatment of childhood infections: oral antibiotics and shorter durations.","volume":"43","author":"Tanti","year":"2024","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:00:31Z","timestamp":1786334431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005362","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}